TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05752552: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

Sponsor: DeuterOncology · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 55 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,738,504

Rescue Site Savings

+$2,481,864

Unlock Full NCT05752552 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05752552 Rescue Dossier →